Altimmune Inc (NASDAQ:ALT) shares traded 13.85% higher at $5.92 on Wall Street last session.
ALT stock price is now -8.89% away from the 50-day moving average and -15.05% away from the 200-day moving average. The market capitalization of the company currently stands at $455.92M.
On January 08, 2025, Stifel recently initiated its ‘Buy’ rating on the stock quoting a target price of $18, while ‘UBS’ rates the stock as ‘Buy’
In other news, WEAVER GREGORY L, Chief Financial Officer bought 10,000 shares of the company’s stock on Mar 13 ’25. The stock was bought for $51,996 at an average price of $5.20. Upon completion of the transaction, the Chief Financial Officer now directly owns 10,000 shares in the company, valued at $59200.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 19 ’24, Director Drutz David sold 16,011 shares of the business’s stock. A total of $110,547 was realized by selling the stock at an average price of $6.90. This leaves the insider owning 41,958 shares of the company worth $0.25 million. A total of 1.03% of the company’s stock is owned by insiders.
During the past 12 months, Altimmune Inc has had a low of $5.14 and a high of $11.16. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 13.10, and a quick ratio of 13.10. The fifty day moving average price for ALT is $6.4975 and a two-hundred day moving average price translates $6.968675 for the stock.
The latest earnings results from Altimmune Inc (NASDAQ: ALT) was released for 2024-12-31. The net profit margin was -475295.00% and return on equity was -59.86% for ALT. The company reported revenue of $5000.0 for the quarter, compared to $37000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -86.49 percent.
